120 related articles for article (PubMed ID: 32306317)
1. Preparation of Recombinant Siglecs and Identification of Their Ligands.
Chang LY; Low PY; Sridharan D; Gerlovin K; Angata T
Methods Mol Biol; 2020; 2132():85-98. PubMed ID: 32306317
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
[TBL] [Abstract][Full Text] [Related]
3. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ
Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118
[TBL] [Abstract][Full Text] [Related]
4. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
Boelaars K; van Kooyk Y
Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
[TBL] [Abstract][Full Text] [Related]
5. Discovery, classification, evolution and diversity of Siglecs.
Angata T; Varki A
Mol Aspects Med; 2023 Apr; 90():101117. PubMed ID: 35989204
[TBL] [Abstract][Full Text] [Related]
6. Impact of Siglecs on autoimmune diseases.
Brzezicka KA; Paulson JC
Mol Aspects Med; 2023 Apr; 90():101140. PubMed ID: 36055802
[TBL] [Abstract][Full Text] [Related]
7. Engineering the sialome of mammalian cells with sialic acid mimetics.
Hornikx DLAH; Visser EA; Psomiadou V; Büll C; Boltje TJ
STAR Protoc; 2023 Sep; 4(3):102330. PubMed ID: 37389993
[TBL] [Abstract][Full Text] [Related]
8. Probing the binding specificities of human Siglecs by cell-based glycan arrays.
Büll C; Nason R; Sun L; Van Coillie J; Madriz Sørensen D; Moons SJ; Yang Z; Arbitman S; Fernandes SM; Furukawa S; McBride R; Nycholat CM; Adema GJ; Paulson JC; Schnaar RL; Boltje TJ; Clausen H; Narimatsu Y
Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33893239
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches.
Angata T; Nycholat CM; Macauley MS
Trends Pharmacol Sci; 2015 Oct; 36(10):645-660. PubMed ID: 26435210
[TBL] [Abstract][Full Text] [Related]
10. Gangliosides as Siglec ligands.
Schnaar RL
Glycoconj J; 2023 Apr; 40(2):159-167. PubMed ID: 36701102
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic potential of sialylated Fc domains of human IgG.
Pleass RJ
MAbs; 2021; 13(1):1953220. PubMed ID: 34288809
[TBL] [Abstract][Full Text] [Related]
12. Advances in understanding and exploiting Siglec-glycan interactions.
Jame-Chenarboo Z; Gray TE; Macauley MS
Curr Opin Chem Biol; 2024 Apr; 80():102454. PubMed ID: 38631213
[TBL] [Abstract][Full Text] [Related]
13. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.
Smith BAH; Deutzmann A; Correa KM; Delaveris CS; Dhanasekaran R; Dove CG; Sullivan DK; Wisnovsky S; Stark JC; Pluvinage JV; Swaminathan S; Riley NM; Rajan A; Majeti R; Felsher DW; Bertozzi CR
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2215376120. PubMed ID: 36897988
[TBL] [Abstract][Full Text] [Related]
14. Siglecs in allergy and asthma.
Bochner BS; O'Sullivan JA; Chang AT; Youngblood BA
Mol Aspects Med; 2023 Apr; 90():101104. PubMed ID: 35835621
[TBL] [Abstract][Full Text] [Related]
15. Phosphoproteomics identifies microglial Siglec-F inflammatory response during neurodegeneration.
Morshed N; Ralvenius WT; Nott A; Watson LA; Rodriguez FH; Akay LA; Joughin BA; Pao PC; Penney J; LaRocque L; Mastroeni D; Tsai LH; White FM
Mol Syst Biol; 2020 Dec; 16(12):e9819. PubMed ID: 33289969
[TBL] [Abstract][Full Text] [Related]
16. The CD24-Siglec G axis protects mice against cuprizone-induced oligodendrocyte loss: targeting danger signal for neuroprotection.
Li N; Zheng P; Liu Y
Cell Mol Immunol; 2018 Jan; 15(1):79-81. PubMed ID: 28757612
[No Abstract] [Full Text] [Related]
17. The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma.
Coccimiglio M; Chiodo F; van Kooyk Y
Br J Dermatol; 2024 Apr; 190(5):627-635. PubMed ID: 38197441
[TBL] [Abstract][Full Text] [Related]
18. Targeting Siglec-Sialylated MUC1 Immune Axis in Cancer.
Ayyalasomayajula R; Cudic M
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611013
[TBL] [Abstract][Full Text] [Related]
19. Siglec-E Ligand Downregulation on Hippocampus Neurons Induced Inflammation in Sevoflurane-Associated Perioperative Neurocognitive Disorders in Aged Mice.
Zhang X; Wang X; Xu Z; Sun F; Jia Y; Tian Y
Inflammation; 2024 Feb; 47(1):30-44. PubMed ID: 37603227
[TBL] [Abstract][Full Text] [Related]
20. Glycobiology of Eosinophilic Inflammation: Contributions of Siglecs, Glycans, and Other Glycan-Binding Proteins.
O'Sullivan JA; Carroll DJ; Bochner BS
Front Med (Lausanne); 2017; 4():116. PubMed ID: 28824909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
